Nexmed Logo
 
 
Abstracts
You will need to have the Adobe® Acrobat Reader installed on your computer to view some of these documents. You can download a copy of the Adobe® Acrobat Reader by clicking the icon below.
The Journal of Sexual Medicine-Volume 6 Issue 2-February 2009
Long-term, Multicenter Study of the Safety and Efficacy of Topical Alprostadil Cream in Male Patients with Erectile Dysfunction by Rooney M, Pfister W, Mahoney M, Nelson M, Yeager J, and Steidle C.
The 17th Congress of The European Academy of Dermatology and Venereology (EADV) Conference
September 17-21, 2008, Paris, France
Determining the Efficacy of Terbinafine HCl Nail Solution Using a Guinea Pig Model of T. Mentagrophytes-Dermatophytosis
Terbinafine HCl in a Novel Alcohol Vehicle Permeates the Human Nail and Achieves Therapeutic Concentrations in the Nail Plate and Nail Bed
Antifungal and Nail Growth Effects of Terbinafine Nail Solution in the Treatment of Onychomycosis
Pharmacokinetic Profile of Topically Applied Terbinafine HCl Nail Solution in Patients With Onychomycosis
American Podiatric Medical Association 96th Annual Scientific Meeting
July 24-27, 2008, Honolulu, Hawaii
Terbinafine Nail Solution Is Highly Effective for The Treatment of Onychomycosis: A Double-Blind, Randomized, Dose-Finding Clinical Trial
Terbinafine HCl Nail Solution (TNS) for Treatment of Onychomycosis: Antifungal Activity In a Bovine Hoof Penetration Bioassay
Pharmacokinetics of Terbinafine HCl Nail Solution in Patients with Onychomycosis
Terbinafine HCl Nail Solution (TNS) for Treatment of Onychomycosis: Evaluation of Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC)
 
American Academy of Dermatology 66th Annual Meeting
February 1-5, 2008 San Antonio, Texas
Terbinafine HCl Nail Solution with and without nail penetration solution: Evaluation of minimum inhibitory concentration and minimum fungicidal concentrations
 
   
 
 
   
 
NexMed is an emerging drug developer that is leveraging its proprietary drug delivery technology to develop a significant pipeline of innovative pharmaceutical products to address large unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT® into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity.